Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05035927 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder
A Phase 2 study, sponsored by TRYP Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT05035927: Completed Phase 2 study, sponsored by TRYP Therapeutics.
NCT05035927 is a Phase 2 study that has completed, run by TRYP Therapeutics. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05035927, a Phase 2 study, has completed, sponsored by TRYP Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
To better understand the potential benefits of psychedelics in overeating disorders, Tryp Therapeutics will conduct a safety and feasibility clinical trial using TRP 8802 among individuals with Binge Eating Disorder. This is a single-center phase 2a open-label study to assess the safety and feasibility of a single dose of TRP 8802 in subjects with BED. Subjects will undergo screening, preparation therapy sessions, dosing, integration therapy sessions, and follow-up for 12 weeks following the dose of TRP 8802. The total participation in the study will be up to approximately 5 months.
Primary Outcome
Safety assessments will be conducted to monitor AEs, including SAEs, protocol specific safety laboratory assessments, protocol specific vital signs and other tests/questionnaires that are deemed crucial to the safety evaluation of the study. Planned timing for all safety assessments is provided in the SOA.
Interventions
- BEHAVIORAL Psychotherapy
- DRUG TRYP-0082
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-03-16 |
| Est. Completion | 2024-06-07 |
| Phase | Phase 2 |
What the finished NCT05035927 record still lists
NCT05035927 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Psychotherapy is the first listed.
NCT05035927 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05035927 about?
NCT05035927 is a clinical study titled "Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder". To better understand the potential benefits of psychedelics in overeating disorders, Tryp Therapeutics will conduct a safety and feasibility clinical trial using TRP 8802 among individuals with Binge Eating Disorder. This is a single-center phase 2a open-label study to assess the safety and feasibil...
What is the current status of trial NCT05035927?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2022-03-16. Estimated completion is 2024-06-07.
What interventions are being tested in trial NCT05035927?
The interventions under investigation include: Psychotherapy (BEHAVIORAL), TRYP-0082 (DRUG).
Who is sponsoring clinical trial NCT05035927?
This trial is sponsored by TRYP Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05035927's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI